Lesson plan
UB-311
UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. It is under development by Vaxxinity (delisted from stock market in May 2024). Meningoencephalitis has been described as a possible side effect of the drug. As of February 2024, the drug is in phase 2 clinical trials. In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).
Article summary
UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. It is under development by Vaxxinity (delisted from stock market in May 2024). Meningoencephalitis has been described as a possible side effect of the drug. As of February 2024, the drug is in phase 2 clinical trials. In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.